Company intelligence / Profile preview
Benxi Shengbaokang Biotechnology
Benxi, Liaoning, Chinatrial.medpath.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Benxi Shengbaokang Biotechnology developed and commercialized a biological product based on the Nocardia rubra cell wall skeleton, which is approved in China for the treatment of uterine cervical erosion. No recent clinical results or new programs are reported.
- Therapeutic areas
- OtherWomen's Health
- Modalities
- Biological productsNocardia rubra cell wall skeleton (biologic/complex biologic)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Benxi Shengbaokang Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benxi Shengbaokang Biotechnology.